Apollo Hospitals, Max Health, hospital stocks jump up to 5% after 30% cap on cancer drugs. What is Jefferies saying?
Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing medicine prices by 70%. Jefferies and Emkay expect manageable earnings impacts, despite near-term margin pressures. Jefferies favours Fortis, Manipal, Apollo, Max Healthcare and Medanta, citing strong demand and attractive valuations.
Key Takeaways
- Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing medicine prices by 70%.
- Jefferies and Emkay expect manageable earnings impacts, despite near-term margin pressures.
- Jefferies favours Fortis, Manipal, Apollo, Max Healthcare and Medanta, citing strong demand and attractive valuations.
Hospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing medicine prices by 70%. Jefferies and Emkay expect manageable earnings impacts, despite near-term margin pressures. Jefferies favours Fortis, Manipal, Apollo, Max Healthcare and Medanta, citing strong demand and attractive valuations.
Original Publisher Attribution
This summary was curated from Economic Times.